Drug intelligence / Profile preview

SARS-CoV-2 protein subunit recombinant vaccine

Development stage: Unknown
Lead developer: Bio Farma
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

SARS-CoV-2 protein subunit recombinant vaccine is a vaccine developed and manufactured by PT Bio Farma. It is designed to induce an immune response against the SARS-CoV-2 virus, the causative agent of COVID-19. The vaccine utilizes a recombinant protein subunit, specifically the Receptor Binding Domain (RBD) of the SARS-CoV-2 virus, to stimulate immunity and provide protection against infection.

Other names: 重组新冠病毒疫苗

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on SARS-CoV-2 protein subunit recombinant vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SARS-CoV-2 protein subunit recombinant vaccine.

Explore the full profile